Macrogenics (MGNX) revenue and earnings history
Macrogenics reported revenue of $150M for fiscal 2025 (year ended Dec 31, 2025), −0.3% on the year before, and net income of −$74.6M.
Over 14 years, from fiscal 2011 to fiscal 2025, revenue grew at a compound rate of +7.1% a year.
Revenue and net income, 15 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $150M−0.3% | −$72.8M | −$74.6M | −$81M | $1.91M | −$83M | $14.3M | — | — | $57.2M | — | 10-K |
| 2024ended Dec 31, 2024 |
The latest quarter, insider trades and fund moves: Macrogenics (MGNX) on OQRO.
Common questions
What was Macrogenics's revenue in fiscal 2025?
$150M for the year ended Dec 31, 2025, as reported in its 10-K filed Mar 9, 2026. That is −0.3% on fiscal 2024 ($150M).
How fast has Macrogenics's revenue grown?
From $57.2M in fiscal 2011 to $150M in fiscal 2025: a compound annual growth rate of +7.1% over 14 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Has Macrogenics been profitable?
Where these figures come from
The SEC’s companyfacts data: every figure Macrogenics tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
